PHARMACEUTICAL News & Analysis

The two biggest players in the market appear poised to dominate for years to come.

All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far. 

Some industries are moaty by nature. One that is deeply out of favour offers a prime example.

Our analyst weighs in on the proposed acquisition and Sigma’s capital raise.

But the tie-up could face significant hurdles, says Morningstar analysts.  

These wide-moat, low-uncertainty names are reliable, writes Susan Dziubinski.

Will there be a second wave? Can we avoid another shutdown? Could a treatment be used to prevent disease? Morningstar strategists respond.

A new Morningstar report identifies which big-name health companies are inoculated against environmental, social and governance risks.

These high-quality companies, including Bristol-Myers Squibb, Roche and Imperial Brands, span a broad range of sectors and represent good value at...

These industries are the most undervalued in the US healthcare sector, owing to potential drug pricing reforms coming out of Washington.